Implantica AG

Equities

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 11:20:05 2024-02-23 am EST 5-day change 1st Jan Change
28.95 SEK +2.48% Intraday chart for Implantica AG -9.95% +21.13%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Implantica AG, Q4 2023 Earnings Call, Feb 16, 2024
Implantica AG Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Implantica Announces Completion of its First RefluxStop Procedures at Artemed Klinikum München Süd in Munich, Germany CI
Implantica Announces First Refluxstop Public Tender Win, Paving the Way for Permanent Reimbursement in Italy CI
Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin CI
Implantica AG (publ.) Adds Another RefluxStop Center in Spain CI
Transcript : Implantica AG, Q3 2023 Earnings Call, Nov 22, 2023
Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK CI
Implantica Wins EU Medical Device Certifications MT
Implantica AG Receives MDR Certification for RefluxStop? CI
Transcript : Implantica AG, Q2 2023 Earnings Call, Aug 24, 2023
Implantica AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Implantica AG Further Expands Its Commercial Footprint in Italy CI
Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago CI
Transcript : Implantica AG, Q1 2023 Earnings Call, May 12, 2023
Tranche Update on Implantica AG (OM:IMP A SDB)'s Equity Buyback Plan announced on April 6, 2023. CI
Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Implantica AG (OM:IMP A SDB) commences an Equity Buyback Plan, under the authorization approved on May 10, 2022. CI
Implantica AG Announces Another Major European Center of Excellence in Italy Starting with the Refluxstop Procedure CI
Implantica AG Presents 3-Year Data on RefluxStop at the Society of Americanastrointestinal and Endoscopic Surgery CI
Implantica AG Announces RefluxStop Launch in Spain CI
Transcript : Implantica AG, Q4 2022 Earnings Call, Feb 17, 2023
Implantica AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Implantica AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Chart Implantica AG
More charts
Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.593 EUR
Average target price
3.834 EUR
Spread / Average Target
+47.87%
Consensus
1st Jan change Capi.
+21.13% 794 M $
-5.24% 9 200 M $
+36.91% 9 624 M $
+12.80% 6 986 M $
-6.69% 5 524 M $
-1.24% 5 118 M $
+3.93% 4 942 M $
+8.03% 3 881 M $
-12.06% 3 288 M $
+1.36% 2 090 M $
Medical Equipment
  1. Stock
  2. Equities
  3. Stock Implantica AG - Nasdaq Stockholm
  4. News Implantica AG
  5. Implantica Wins EU Medical Device Certifications
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer